

Tracey L. Petryshen^{1,2,*} and Gabriëlla A.M. Blokland^{1,2}, on behalf of the GENUS Consortium³


¹ Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; ² Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, United States; ³ genus.mgh.harvard.edu/investigators. * tpetryshen@mgh.harvard.edu

Background

- The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium is clarifying the neurobiological role of schizophrenia (SCZ) risk genes by examining associations with cognitive and neuroanatomical measures in a unique sample collection.
- Fifteen research groups contributed cognitive and genetic data from a total of 4,575 SCZ cases, 4640 controls, and 875 genetic risk individuals, of which a subset (~3,000) also has structural MRI data.
- A crucial first step has been the development of phenotype and genotype processing and quality assessment protocols to harmonize data across the samples, since the sites used different neuropsychological test batteries, SNP arrays, and MRI acquisition parameters.
- A parallel step has been extensive literature review and meta-analysis to select cognitive and brain structure traits for genetic analyses that have high heritability, reliability, and robust case-control differences.
- Initial genetic studies will focus on association analyses of each selected phenotype with SNPs having prior SCZ GWAS evidence ($p < 5 \times 10^{-8}$) and polygenic SNP sets that are functionally related, as well as multivariate regression analysis to identify phenotype-genotype profiles or clusters.

Samples - 4575 SCZ, 875 genetic high risk, 4640 control

Sample	Site	PI(s)
CAMH	Toronto, Canada	Voineskos
CATIE	Multi-site, USA	NIMH
CIDAR-VA	Boston, USA	McCarley, Kikinis
COGS-UK	Cardiff, UK	Walters
GAP, MTS, MFS	London, UK	Toulopoulou
IMH	Singapore	Keong, Sim, Yang
L&R	Boston, USA	DeLisi
MCIC	Multi-site, USA	Turner, Ehrlich, Gollub
MGH	Boston, USA	Roffman, Holt
NEFS	Boston, USA	Goldstein, Seidman, Buka
PAGES	Munich, Germany	Rujescu, Giegling
PHRS	Pittsburgh, USA	Keshavan, Montrose
TCD-NUIG	Dublin/Galway, Ireland	Donohoe
UMCU-SZ1,2	Utrecht, Netherlands	Kahn, van Haren
ZHH	New York, USA	Mahotra, Trampush




Cognitive Phenotypes

MATRIX domain	Neuropsychological tests	Effect size ^a standardized mean difference	Heritability ^b
Speed of Processing	BACS Symbol Coding/ WAIS Digit Symbol Coding*; Trail Making A*; Category Fluency*; Letter Fluency*	-0.96	0.52 (0.45 - 0.59)
Attention/Vigilance	Continuous Performance Test - Identical Pairs*; Other CPTs	-0.71	0.30 (0.23 - 0.37)
Working Memory	UMD Letter-Number Span/ WAIS Letter-Number Sequencing*; WMS-III Spatial Span/ WMS-R Visual Memory Span*; WAIS Digit Span; Arithmetic	-0.79	0.42 (0.37 - 0.47)
Verbal Learning	Hopkins Verbal Learning Test-R/ Other word list learning tests*; WMS Logical Memory/Stories; WMS Verbal Paired Associates	-1.20	0.34 (0.24 - 0.44)
Visual Learning	Brief Visuospatial Memory Test-R*; Benton Visual Retention Test; WMS Visual Paired Associates; Visual Reproduction; Figural Memory; Faces	-0.91	0.35 (0.30 - 0.41)
Reasoning/ Problem Solving	NAB Mazes; Wisconsin Card Sorting Test; Trail Making B	-0.83	0.26 (0.19 - 0.34)

BACS = Brief Assessment of Cognition for Schizophrenia; UMD = University of Maryland
 H-VLT = Hopkins Verbal Learning Test
 CVLT = California Verbal Learning Test
 CPT-IP = Continuous Performance Test - Independent Pairs

Data Processing Pipelines



Neuroimaging Phenotypes

Region of Interest	Effect size ^a Cohen's d	Heritability ^b
Superior temporal gyrus	-0.58	0.53 - 0.65
Transverse temporal gyrus	-0.29	0.44 - 0.58
inferior frontal gyrus	-0.41	0.17 - 0.51
Middle frontal gyrus	-0.32	0.29 - 0.57
Anterior cingulate	-0.34	0.12 - 0.50
Inferior parietal lobule	--	0.41 - 0.65
Insula	-0.44	0.50 - 0.65
Hippocampus	-0.52	0.56 - 0.64
Amygdala	-0.31	0.65
Lateral Ventricles	+0.45	0.44 - 0.70
Total cortical GM volume	-0.43	0.67
Total brain volume	-0.30	0.83
Intracranial volume	-0.17	0.79

Discussion

- Due to the high cross-site variability in the neuropsychological test batteries, the GWAS arrays, and the MRI acquisition parameters, we have developed comprehensive data harmonization approaches for the phenotypic and genotypic data.
- We have demonstrated that our neuropsychological data harmonization approach is successful, with significant case-control differences for individual tests and Spearman's "g", and genetic risk individuals performing at a level between that of cases and controls, as expected.
- Genotype data processing and structural MRI processing are expected to be completed in summer 2015.
- Association analyses of known SCZ risk variants and polygene sets with cognitive and brain structure traits in one of the largest sample collections of its kind may contribute towards understanding the function of existing SCZ risk variants in neural processes underlying SCZ.

References

- Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108 schizophrenia-associated genetic loci, *Nature*, 2014;511(7510):421-7
- Mesholam-Gately, R.I., et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology* 2009;23(3):315
- Blokland, G.A.M., Petryshen, T.L., et al., in preparation.
- Hajima, S.V., et al. Brain volumes in schizophrenia: A meta-analysis in over 18000 subjects. *Schizophrenia Bulletin*, 2012; doi:10.1093/schbul/sbs118.
- Blokland, G.A.M., et al. Genetic and environmental influences on neuroimaging phenotypes: A meta-analytic perspective on twin imaging studies. *Twin Res Hum Genet*, 2012; 15(3): 351-71.

Acknowledgements

This collaborative project "Genetic Determinants of Schizophrenia Intermediate Phenotypes" is funded by the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH) under Award Number R01MH02380 (PI: Tracey Petryshen). The content of this poster is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Schizophrenia-High Risk-Control Group Differences

